SCHEMBL14949515

SCHEMBL14949515

CSc1nc(N)cc(Oc2ccc(-c3nnc(Nc4cc(C)cc(C(F)(F)F)c4)[nH]3)cc2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.57
KIT P10721 1/20 0.57
PDGFRA P16234 1/20 0.57
CDK11B P21127 1/20 0.57
FLT3 P36888 1/20 0.57
CDKL2 Q92772 1/20 0.57
LMNA P02545 2/20 0.33
TSHR P16473 2/20 0.33
MEN1 O00255 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
ATM Q13315 1/20 0.33
MAPK14 Q16539 2/20 0.31
KDR P35968 2/20 0.31
BRAF P15056 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12336421 0.95 PDGFRB (0.61) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL627644 0.92 PDGFRB (0.50) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL625598 0.89 PDGFRB (0.73) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949292 0.86 PDGFRB (0.50) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336289 0.86 PDGFRB (0.56) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336691 0.84 PDGFRB (0.62) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336261 0.84 PDGFRB (0.55) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949500 0.84 PDGFRB (0.51) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14952389 0.84 PDGFRB (0.57) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949485 0.84 PDGFRB (0.55) PDGFRBKITPDGFRACDK11BFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.